Showing 1 - 20 results of 53,264 for search '(( significant changes cases ) OR ( significant ((mean decrease) OR (we decrease)) ))', query time: 1.07s Refine Results
  1. 1

    Roughness change in means of Ra (nm) and RMS (nm) for both tested systems. (different capital superscript letters indicate within group significancy, different lower-case superscript letters indicate significancy between groups). by Beliz Özel (16475132)

    Published 2024
    “…(different capital superscript letters indicate within group significancy, different lower-case superscript letters indicate significancy between groups).…”
  2. 2

    Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

    Published 2021
    “…Shaded regions correspond to the standard error of the mean and dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs. …”
  3. 3

    Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? by Isa Sincer (7234577)

    Published 2019
    “…Several studies have shown the association between mean platelet volume (MPV) and cardiovascular diseases. …”
  4. 4
  5. 5
  6. 6

    Mean platelet volume and neutrophil to lymphocyte ratio decrease in patients with depression with antidepressant treatment by AHMET ÖZTÜRK (8077292)

    Published 2022
    “…Discussion MPV of depressed patients was higher than controls. When we look at admission and discharge scores of clinical scales, decrement is statistically significant for both HAM-D and CGI-S. …”
  7. 7
  8. 8

    Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  9. 9

    Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  10. 10
  11. 11
  12. 12
  13. 13

    Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  14. 14

    Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  15. 15

    Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  16. 16

    Changes in the mean logMAR BCVA ± standard error from baseline to 6 months after IOI occurred. by Kazushi Hirono (17867141)

    Published 2024
    “…<p>The mean logMAR BCVA when IOI occurred decreased significantly compared with before IOI occurred (<i>P</i> = 0.02). …”
  17. 17
  18. 18
  19. 19
  20. 20